SEC Tracker
Get the app

CRISPR Therapeutics CRSP

CRISPR Therapeutics reported a net loss of $111.44 million for the three months ended Sep 30, 2026.

Form
10-Q
Filed
Importance
Notable
  1. Revenue was $12.67 million for the three months ended Sep 30, 2026.
  2. Net loss was $111.44 million for the three months ended Sep 30, 2026.
  3. Cash and equivalents were $192.03 million as of Sep 30, 2026.

Written from the 10-Q on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when CRISPR Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. Soleno Therapeutics SLNO public float $4.1B, Jun 30, 2025
  2. Adma Biologics ADMA public float $4.2B, Jun 30, 2025
  3. Lantheus Holdings LNTH public float $4.3B, Jun 30, 2025
  4. Merus MRUS
  5. Axsome Therapeutics AXSM public float $4.4B, Jun 30, 2025